Zhang Guan-Nan, Ashby Charles R, Zhang Yun-Kai, Chen Zhe-Sheng, Guo Huiqin
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing, 100730, P. R. China.
Chin J Cancer. 2015 Sep 14;34(11):488-95. doi: 10.1186/s40880-015-0048-0.
Multidrug resistance (MDR), defined as the resistance of cancer cells to compounds with diverse structures and mechanisms of actions, significantly limits the efficacy of antitumor drugs. A major mechanism that mediates MDR in cancer is the overexpression of adenosine triphosphate (ATP)-binding cassette transporters. These transporters bind to their respective substrates and catalyze their efflux from cancer cells, thereby lowering the intracellular concentrations of the substrates and thus attenuating or even abolishing their efficacy. In addition, cancer cells can become resistant to drugs via mechanisms that attenuate apoptosis and cell cycle arrest such as alterations in the p53, check point kinase, nuclear factor kappa B, and the p38 mitogen-activated protein kinase pathway. In this review, we discuss the mechanisms by which β-elemene, a compound extracted from Rhizoma zedoariae that has clinical antitumor efficacy, overcomes drug resistance in cancer.
多药耐药性(MDR)是指癌细胞对具有不同结构和作用机制的化合物产生耐药性,这显著限制了抗肿瘤药物的疗效。介导癌症多药耐药性的一个主要机制是三磷酸腺苷(ATP)结合盒转运蛋白的过度表达。这些转运蛋白与其各自的底物结合,并催化底物从癌细胞中流出,从而降低底物的细胞内浓度,进而减弱甚至消除其疗效。此外,癌细胞可通过减弱凋亡和细胞周期停滞的机制产生耐药性,如p53、检查点激酶、核因子κB和p38丝裂原活化蛋白激酶途径的改变。在本综述中,我们讨论了莪术提取的具有临床抗肿瘤疗效的化合物β-榄香烯克服癌症耐药性的机制。